Furthermore, the majority of PDACs in the NAT‐group were classified as CAP‐2 (55%) and CAP‐3 (41%; Table 1), indicating that tumor regression, the desired response to NAT, was either partial (CAP‐2) or poor/absent (CAP‐3). The gene discussed is BRD2; the disease is neoplasm.